Wells Fargo & Company MN raised its position in Acceleron Pharma Inc (NASDAQ:XLRN) by 13.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,244 shares of the biopharmaceutical company’s stock after acquiring an additional 5,247 shares during the quarter. Wells Fargo & Company MN owned approximately 0.10% of Acceleron Pharma worth $1,614,000 as of its most recent SEC filing.
A number of other institutional investors have also recently modified their holdings of XLRN. Schwab Charles Investment Management Inc. lifted its stake in Acceleron Pharma by 9.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 143,842 shares of the biopharmaceutical company’s stock worth $4,372,000 after acquiring an additional 12,001 shares during the last quarter. Rhumbline Advisers lifted its stake in Acceleron Pharma by 15.3% in the second quarter. Rhumbline Advisers now owns 37,217 shares of the biopharmaceutical company’s stock worth $1,131,000 after acquiring an additional 4,945 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Acceleron Pharma by 15.2% in the second quarter. Bank of New York Mellon Corp now owns 138,561 shares of the biopharmaceutical company’s stock worth $4,211,000 after acquiring an additional 18,269 shares during the last quarter. Legal & General Group Plc lifted its stake in Acceleron Pharma by 9.7% in the second quarter. Legal & General Group Plc now owns 10,470 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 923 shares during the last quarter. Finally, BNP Paribas Arbitrage SA raised its holdings in Acceleron Pharma by 969.9% during the second quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 3,288 shares in the last quarter. Institutional investors own 85.70% of the company’s stock.
A number of analysts have weighed in on the stock. Credit Suisse Group reissued an “outperform” rating and set a $55.00 price objective on shares of Acceleron Pharma in a report on Thursday. HC Wainwright raised their price objective on shares of Acceleron Pharma from $57.00 to $62.00 and gave the stock a “buy” rating in a report on Tuesday, November 7th. Oppenheimer reissued a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, November 14th. BidaskClub raised shares of Acceleron Pharma from a “hold” rating to a “buy” rating in a report on Wednesday, December 27th. Finally, Royal Bank of Canada reissued a “hold” rating on shares of Acceleron Pharma in a report on Thursday, November 2nd. Two research analysts have rated the stock with a sell rating, six have given a hold rating and twelve have assigned a buy rating to the company’s stock. Acceleron Pharma currently has a consensus rating of “Buy” and a consensus price target of $44.81.
In other news, SVP Christopher Rovaldi sold 11,000 shares of Acceleron Pharma stock in a transaction on Friday, January 12th. The shares were sold at an average price of $45.00, for a total value of $495,000.00. Following the transaction, the senior vice president now directly owns 35,701 shares of the company’s stock, valued at approximately $1,606,545. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Jean George sold 105,122 shares of Acceleron Pharma stock in a transaction on Friday, December 15th. The shares were sold at an average price of $35.73, for a total transaction of $3,756,009.06. Following the completion of the transaction, the director now directly owns 1,250 shares in the company, valued at $44,662.50. The disclosure for this sale can be found here. Insiders sold a total of 146,021 shares of company stock worth $5,529,598 over the last ninety days. Corporate insiders own 3.90% of the company’s stock.
Acceleron Pharma Inc (XLRN) opened at $43.04 on Friday. The company has a market cap of $1,915.70, a price-to-earnings ratio of -16.62 and a beta of 1.59. Acceleron Pharma Inc has a 1-year low of $23.07 and a 1-year high of $46.93.
Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.02. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.52 million. Acceleron Pharma had a negative net margin of 759.34% and a negative return on equity of 40.70%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.55) EPS. research analysts predict that Acceleron Pharma Inc will post -2.65 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.truebluetribune.com/2018/01/20/wells-fargo-company-mn-purchases-5247-shares-of-acceleron-pharma-inc-xlrn.html.
Acceleron Pharma Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.